Ascentage Pharma Group International has announced the release of results from multiple clinical studies at the 2025 European Hematology Association (EHA) Hybrid Congress. The company presented findings from 13 studies focusing on its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918. Notably, olverembatinib demonstrated significant therapeutic potential and clinical benefits in treating Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia $(ALL)$, with high complete remission and molecular response rates. Additionally, a preclinical study on APG-5918 showed its potent antitumor activity in T-cell lymphoma, supporting further clinical development. The results were featured in various formats, including poster presentations at the congress.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。